LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Researchers Identify RNAs Involved in Tumor Growth

By LabMedica International staff writers
Posted on 05 Sep 2017
Image: The long non-coding RNA (lncRNA) PNUTS (PPP1R10) (Photo courtesy of LNCipedia.org, an online database for annotated human lncRNA sequences).
Image: The long non-coding RNA (lncRNA) PNUTS (PPP1R10) (Photo courtesy of LNCipedia.org, an online database for annotated human lncRNA sequences).
Cancer researchers have linked a specific long non-coding RNA (lncRNA) to the growth and metastasis of certain types of cancer.

Long non-coding RNAs (lncRNAs) are considered to be non-protein coding transcripts longer than 200 nucleotides. This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study.

Investigators at the Medical University of South Carolina (Charleston, SC, USA) were studying the contribution of lncRNAs to tumor progression and the regulatory mechanisms driving their expression.

They reported in the August 21, 2017, online edition of the journal Nature Cell Biology that they had characterized the binding of the heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) to a nucleic acid structural element located in exon 12 of PNUTS (also known as PPP1R10) pre-RNA, which regulated its alternative splicing. HnRNP E1 release from this structural element, following its silencing, nucleocytoplasmic translocation, or in response to transforming growth factor beta (TGFbeta), allowed alternative splicing and generated a non-coding isoform of PNUTS.

Functionally the lncRNA called PNUTS was shown to serve as a competitive sponge for the microRNA miR-205 during epithelial–mesenchymal transition (EMT). In mesenchymal breast tumor cells and in breast tumor samples, the expression of lncRNA-PNUTS was elevated and correlated with levels of ZEB1 (Zinc finger E-box-binding homeobox 1) mRNAs. Simply put, breast and lung tumors grew faster and larger when their cells contained more PNUTS lncRNA.

Thus, PNUTS was determined to be a bifunctional RNA encoding both PNUTS mRNA and lncRNA-PNUTS, each eliciting distinct biological functions. While PNUTS mRNA was ubiquitously expressed, lncRNA-PNUTS appeared to be tightly regulated dependent on the status of hnRNP E1 and tumor context.

"My prediction is that this mechanism did not evolve to make just one long non-coding RNA," said senior author Dr. Philip H. Howe, professor of biochemistry and molecular biology at the Medical University of South Carolina. "There are probably others that are generated in this same fashion."

Related Links:
Medical University of South Carolina

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more